Shamiur Rahman LipuPublished:
2020-06-30 10:06:56 BdST
Gilead prices remdesivir at $390 per vial in US
Gilead Sciences Inc said on Monday it has priced its COVID-19 treatment candidate remdesivir at $390 per vial in the United States and other developed countries.
Based on current treatment patterns, the vast majority of patients are expected to receive a five-day treatment course using six vials of remdesivir, which equates to $2,340 per patient, reports Reuters citing the company.
The price for US private insurance companies will be $520 per vial, the drugmaker said, which equates to a total of $3,120 per patient.
Gilead has entered into an agreement with the US Department of Health and Human Services (HHS) whereby the department and states will manage allocation to hospitals until September end.
After this period, once supplies are less constrained, HHS will stop managing the allocation, the company said.
Remdesivir's price has been a topic of intense debate since the US Food and Drug Administration approved its emergency use Covid-19 patients in May.
Experts have suggested that Gilead would need to avoid the appearance of taking advantage of a health crisis for profits.
Wall Street analysts have said the antiviral drug could generate billions of dollars in revenue over the next couple of years if the pandemic continues.
Unauthorized use or reproduction of The Finance Today content for commercial purposes is strictly prohibited.